Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit. J Clin Oncol. 2013..
Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. Am J Blood Res. 2013;3(3):260-4..
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015.
Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy. Biol Blood Marrow Transplant. 2015..
Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2015..
Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation. Adv Hematol. 2016;2016:4025073..
Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016.
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016.
Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma. 2016:1-6..
Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results. Biol Blood Marrow Transplant. 2019.
Curative Potential of Hematopoietic Stem Cell Transplantation for Advanced Psoriasis. Am J Hematol. 2019..
Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol. 2019.
Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019.
A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2020:1-8.
Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020..
Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv. 2020;4(15):3474-3485..
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020.